Kate Fulford and Andrew Stafford report on the findings from the first two years of the Dementia Training Australia Medication Management Consultancy; a pivotal pharmacist-led consultancy service reducing antipsychotic usage in residential aged care facilities across Australia

Extract from:
Australian Journal of Dementia Care

Published:
6 December, 2019

Responsive behaviours are experienced by the majority of people living with dementia at some point throughout their journey with the condition. For decades, antipsychotic medications have been used in residential aged care to alleviate responsive behaviours. This is despite these medications being of limited effectiveness for most responsive behaviours, and concerns regarding an increased risk for injury and death for a person with dementia who is prescribed an antipsychotic (TGA 2015).

There is also an increasing body of evidence that addressing responsive behaviours with non- pharmaceutical approaches is at least as effective as using antipsychotic medications (TG Ltd 2016). Consequently, most clinical guidelines that address responsive behaviours recommend that antipsychotic medications should only be considered when all non-medication approaches have failed, and only for severe symptoms of aggression and agitation. However, many residential aged care sites report difficulties in adhering to these guidelines due to various barriers. These include a lack of knowledge regarding the safe withdrawal of these medications, organisational processes that inadequately support decision making for responsive behaviour management, and lack of commitment to changing staff behaviour.

In response to this body of evidence, Dementia Training Australia (DTA)developed a pharmacist-led, evidence-based service that aims to embed knowledge and processes to optimise the use of antipsychotic medications for responsive behaviours. The Medication Management Consultancy (MMC) is a three-tiered process which dta medicaiton management consultancy 60% reductionbenchmarks and then follows over time two key measures relating to antipsychotic use. These are: the number of residents prescribed antipsychotic medications for responsive behaviours; and staff knowledge about the appropriate use of psychotropic medications for responsive behaviours within the residential aged care facility (RACF).

The MMC has been undertaken by three large residential aged care organisations across Australia over the past two years, where considerable benefits in both measures have been identified. Across 10 locations, five RACFs have seen greater than a 50% reduction in the proportion of residents using antipsychotics, with up to 60% reduction facility-wide at one location, and 67% reduction across the dementia support unit (DSU) within another.

Extract from:
Australian Journal of Dementia Care

Published:
6 December, 2019

  

More Opinion pieces 

Beyond words

There is optimism that the Royal Commission into Aged Care Quality and Safety can stimulate real change beyond words, writes DTA Executive Director, Professor Belinda Goodenough, for the Australian Journal of Dementia Care.

Change is here – amended legislation on chemical restraints in Australia

DTA’s Medication Management Consultancy has seen as much as a 60% relative reduction in antipsychotic medications prescribed within residential aged care facilities across Australia.